VectorBuilder has announced the construction of a new manufacturing and R&D centre in Guangzhou, China

Laboratory

A global leader in gene delivery solutions, VectorBuilder, has announced the construction of a new manufacturing and R&D centre in Guangzhou, China. The Gene Delivery Research and Manufacturing Campus will considerably expand VectorBuilder’s R&D capabilities, as well as its production capacity for both cGMP-grade gene delivery vectors and research use, enabling the business to continue supporting innovative research globally.

The Gene Delivery Research and Manufacturing Campus will include a state-of-the-art CDMO facility with thirty production suites, designed for cGMP manufacturing of plasmids, AAV, cell lines, mRNA, and other types of non-viral and viral vectors. In addition, it will offer CRO services for functional validation and vector optimisation, and GLP and non-GLP studies for vector biodistribution, PD/ADME/PK and toxicology.

“VectorBuilder has announced the construction of a new manufacturing and R&D centre in Guangzhou, China.“

Furthermore, the campus will be home to a dedicated research institute which develops new gene delivery technologies, to improve upon current tools in terms of targeting payload, efficient manufacturing costs and safety, to meet the demand in clinical applications, including vector-based vaccines, gene therapy, and virus-based cancer therapeutics. Aimed at training engineers and scientists in the rapidly expanding gene delivery field, the research institute will carry out educational activities.

The construction is predicted to cost five hundred million dollars, which will be split into two phases over the next four years. There will be roughly 100,000 m2 of floor space capable of housing over two-thousand staff members. This project is part of VectorBuilder’s global expansion, with additional R&D and manufacturing sites planned in Europe, US and Japan.

Chief Scientist at VectorBuilder, Dr. Bruce Lahn, stated: “Modern biology is largely built on gene delivery technologies, but until recently, such technologies are mostly limited to research use. With the recent advancement of genetic medicine, gene vectors are now rapidly moving into clinical use, including CAR-T, gene therapy, mRNA vaccines and oncolytic viruses. Some experts predict that in ten to twenty years, vector-based drugs will become the third pillar of medicine, after small-molecule drugs and protein-based biologics. We are therefore expanding our R&D capabilities, as well as our manufacturing capacity, to continue leading the way in the development of innovative gene delivery technologies that will make research more efficient, and genetic medicine more effective and affordable.”

Return to news